Cargando…
Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
Background and objectives: Governments in Asia Pacific (APAC) are increasingly using pharmaceutical pricing strategies to contain rising healthcare costs. The objective of this narrative review is to discuss formal pricing strategies for reimbursed prescription medication in APAC, supported by relev...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461095/ https://www.ncbi.nlm.nih.gov/pubmed/31007877 http://dx.doi.org/10.1080/20016689.2019.1601060 |
_version_ | 1783410443592663040 |
---|---|
author | Verghese, Naina R. Barrenetxea, Jon Bhargava, Yukti Agrawal, Sagun Finkelstein, Eric Andrew |
author_facet | Verghese, Naina R. Barrenetxea, Jon Bhargava, Yukti Agrawal, Sagun Finkelstein, Eric Andrew |
author_sort | Verghese, Naina R. |
collection | PubMed |
description | Background and objectives: Governments in Asia Pacific (APAC) are increasingly using pharmaceutical pricing strategies to contain rising healthcare costs. The objective of this narrative review is to discuss formal pricing strategies for reimbursed prescription medication in APAC, supported by relevant examples of implementation differences across countries. In the discussion section, we examine key advantages and disadvantages of each strategy. Methods: A narrative review of the peer-reviewed and grey literature was undertaken to retrieve information, including strategy definitions, practising countries, country-specific implementation considerations, and merits and demerits of each strategy. Results: Seven strategies (Internal Reference Pricing, External Reference Pricing, Special Pricing Agreements, Pharmacoeconomic Evaluation, Cost plus pricing, Price Maintenance Premium, and Tendering and negotiations) were identified as most commonly practised in APAC through the review process. Most countries use multiple strategies that differ in how they are implemented. Conclusion: APAC countries use multiple strategies simultaneously with varying implementation methods, including different formulae and sub-types of medication that a strategy applies to, whether the strategy is a mandate or guideline, and the extent of negotiations and transparency. Strategies are instituted partly with the aim of cost containment, and may also promote price stability, innovation, and increased access in the short and longer term. Abbreviations: APAC - Asia Pacific; WHO - World Health Organisation; IRP - Internal Reference Pricing; ERP - External Reference Pricing; SPA - Special Pricing Agreement; MES - Managed Entry Scheme; PVA - Price-Volume Agreement; RSA - Risk Sharing Agreement; NHIS - National Health Insurance System; PE - Pharmacoeconomic Evaluation; CEA - Cost-Effectiveness Analysis; QALY - Quality-adjusted Life Year; BIA - Budget Impact Analysis; PMP - Price Maintenance Premium; R&D - Research & Development |
format | Online Article Text |
id | pubmed-6461095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Routledge |
record_format | MEDLINE/PubMed |
spelling | pubmed-64610952019-04-19 Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview Verghese, Naina R. Barrenetxea, Jon Bhargava, Yukti Agrawal, Sagun Finkelstein, Eric Andrew J Mark Access Health Policy Review Article Background and objectives: Governments in Asia Pacific (APAC) are increasingly using pharmaceutical pricing strategies to contain rising healthcare costs. The objective of this narrative review is to discuss formal pricing strategies for reimbursed prescription medication in APAC, supported by relevant examples of implementation differences across countries. In the discussion section, we examine key advantages and disadvantages of each strategy. Methods: A narrative review of the peer-reviewed and grey literature was undertaken to retrieve information, including strategy definitions, practising countries, country-specific implementation considerations, and merits and demerits of each strategy. Results: Seven strategies (Internal Reference Pricing, External Reference Pricing, Special Pricing Agreements, Pharmacoeconomic Evaluation, Cost plus pricing, Price Maintenance Premium, and Tendering and negotiations) were identified as most commonly practised in APAC through the review process. Most countries use multiple strategies that differ in how they are implemented. Conclusion: APAC countries use multiple strategies simultaneously with varying implementation methods, including different formulae and sub-types of medication that a strategy applies to, whether the strategy is a mandate or guideline, and the extent of negotiations and transparency. Strategies are instituted partly with the aim of cost containment, and may also promote price stability, innovation, and increased access in the short and longer term. Abbreviations: APAC - Asia Pacific; WHO - World Health Organisation; IRP - Internal Reference Pricing; ERP - External Reference Pricing; SPA - Special Pricing Agreement; MES - Managed Entry Scheme; PVA - Price-Volume Agreement; RSA - Risk Sharing Agreement; NHIS - National Health Insurance System; PE - Pharmacoeconomic Evaluation; CEA - Cost-Effectiveness Analysis; QALY - Quality-adjusted Life Year; BIA - Budget Impact Analysis; PMP - Price Maintenance Premium; R&D - Research & Development Routledge 2019-04-11 /pmc/articles/PMC6461095/ /pubmed/31007877 http://dx.doi.org/10.1080/20016689.2019.1601060 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Verghese, Naina R. Barrenetxea, Jon Bhargava, Yukti Agrawal, Sagun Finkelstein, Eric Andrew Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview |
title | Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview |
title_full | Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview |
title_fullStr | Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview |
title_full_unstemmed | Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview |
title_short | Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview |
title_sort | government pharmaceutical pricing strategies in the asia-pacific region: an overview |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461095/ https://www.ncbi.nlm.nih.gov/pubmed/31007877 http://dx.doi.org/10.1080/20016689.2019.1601060 |
work_keys_str_mv | AT verghesenainar governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview AT barrenetxeajon governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview AT bhargavayukti governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview AT agrawalsagun governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview AT finkelsteinericandrew governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview |